Dual CRISPR-Cas3 is a promising tool to induce a gigantic genomic deletion and restore dystrophin protein

Nearly half of all cardiology private practices were under private equity as of 2023, and there was a slight decrease in the proportion of groups

Spring­Works Ther­a­peu­tics has un­veiled pos­i­tive da­ta from a mid-stage tri­al of its drug can­di­date for neu­rofi­bro­mato­sis type 1 (NF1) as­so­ci­at­ed plex­i­form neu­rofi­bro­mas (PN), paving the